LEADER 05941nam 2200841Ia 450 001 9910970999303321 005 20251017110101.0 010 $a9786610183555 010 $a9780309182836 010 $a0309182832 010 $a9781280183553 010 $a1280183551 010 $a9780309566100 010 $a030956610X 035 $a(CKB)111069351128584 035 $a(SSID)ssj0000176890 035 $a(PQKBManifestationID)11165321 035 $a(PQKBTitleCode)TC0000176890 035 $a(PQKBWorkID)10209408 035 $a(PQKB)10674403 035 $a(MiAaPQ)EBC3377265 035 $a(Au-PeEL)EBL3377265 035 $a(CaPaEBR)ebr10068512 035 $a(CaONFJC)MIL18355 035 $a(OCoLC)923269360 035 $a(Perlego)4740573 035 $a(DNLM)1166764 035 $a(EXLCZ)99111069351128584 100 $a20040120d2002 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aImmunization safety review $ehepatitis B vaccine and demyelinating neurological disorders /$fKathleen Stratton, Donna A. Almario, and Marie C. McCormick, editors 205 $a1st ed. 210 $aWashington, D.C. ;$a[Great Britain] $cNational Academies Press$dc2002 215 $a1 online resource (xiv, 106 pages) $cillustrations 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a9780309084697 311 08$a0309084695 320 $aIncludes bibliographical references (p. 85-90). 327 $aIMMUNIZATION SAFETY REVIEW -- Copyright -- Acknowledgments -- Contents -- Executive Summary -- ABSTRACT -- DEMYELINATING NEUROLOGICAL DISORDERS -- HEPATITIS B VIRAL INFECTION -- HEPATITIS B VACCINE -- EVIDENCE REVIEWED BY THE COMMITTEE -- CAUSALITY ASSESSMENT -- BIOLOGICAL MECHANISMS ASSESSMENT -- SIGNIFICANCE ASSESSMENT -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- Policy Review -- Research -- Surveillance -- Basic and Clinical Science -- Communication -- REFERENCES -- Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders -- THE CHARGE TO THE COMMITTEE -- THE STUDY PROCESS -- THE FRAMEWORK FOR SCIENTIFIC ASSESSMENT -- Causality -- Biological Mechanisms -- Terminology -- Categories of Evidence -- Published and Unpublished Data -- UNDER REVIEW: HEPATITIS B VACCINE AND DEMYELINATING NEUROLOGICAL DISORDERS -- Adverse Neurological Events -- Multiple Sclerosis -- Acute Disseminated Encephalomyelitis -- Optic Neuritis -- Transverse Myelitis -- Guillain-Barré Syndrome -- Peripheral Neuritis -- Hepatitis B Virus Infection and Hepatitis B Vaccines -- SCIENTIFIC ASSESSMENT -- Causality -- Case Reports -- Multiple Sclerosis -- Causality Argument -- First Episode of a Central Nervous System Demyelinating Disorder -- Acute Disseminated Encephalomyelitis -- Optic Neuritis -- Transverse Myelitis -- Brachial Neuritis -- Biological Mechanisms -- Immune-Mediated Processes in MS and Other Demyelinating White-Matter Diseases -- Theoretical Mechanisms for Infection-Induced Immune-Mediated Injury -- Theoretical Mechanisms for Vaccine-Induced Demyelinating Diseases -- Evidence from Animal Models for a Possible Role for Hepatitis B Vaccine in Demyelination -- Evidence from Humans -- Known Effects of Other Vaccines -- Conclusions Regarding Biological Mechanisms -- SIGNIFICANCE ASSESSMENT. 327 $aDisease Burden Associated with Multiple Sclerosis -- Hepatitis B Vaccine Safety Concerns in France -- Hepatitis B Virus Infection -- Prevention Strategies -- Acceptance of the Hepatitis B Vaccine in the United States -- Information on the Safety of the Hepatitis B Vaccine -- Conclusions -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- Policy Review -- Research -- Surveillance -- Basic and Clinical Science -- Communication -- SUMMARY -- REFERENCES -- Appendix A Committee Conclusions and Recommendations from Previous Reports -- MEASLES-MUMPS-RUBELLA VACCINE AND AUTISM -- Conclusions -- Recommendations -- Public Health Response -- Policy Review -- Research Regarding MMR and ASD -- Communications -- THIMEROSAL-CONTAINING VACCINES AND NEURODEVELOPMENTAL DISORDERS -- Conclusions -- Public Health Response Recommendations -- Policy Review and Analysis -- Public Health and Biomedical Research -- Epidemiological Research -- Clinical Research -- Basic Science Research -- MULTIPLE IMMUNIZATIONS AND IMMUNE DYSFUNCTION -- Conclusions -- Scientific Assessment -- Causality Conclusions -- Biological Mechanisms Conclusions -- Significance Assessment -- Public Health Response Recommendations -- Policy Review -- Research -- Epidemiological Research -- Basic Science and Clinical Research -- Communication -- Appendix B Public Meeting Agenda March 11, 2002 -- Appendix C Chronology of Important Events Regarding Vaccine Safety. 606 $aHepatitis B$xVaccination 606 $aHepatitis B vaccine 606 $aDemyelination$xVaccination 606 $aImmunization$xComplications 606 $aVaccination$xComplications 606 $aHepatitis B Vaccines$xadverse effects 606 $aDemyelinating Diseases$xetiology 606 $aHealth Policy 607 $aUnited States 615 0$aHepatitis B$xVaccination. 615 0$aHepatitis B vaccine. 615 0$aDemyelination$xVaccination. 615 0$aImmunization$xComplications. 615 0$aVaccination$xComplications. 615 12$aHepatitis B Vaccines$xadverse effects 615 22$aDemyelinating Diseases$xetiology 615 22$aHealth Policy 676 $a614.593 701 $aStratton$b Kathleen R$01797964 701 $aAlmario$b Donna A$01806832 701 $aMcCormick$b Marie C$01806833 712 02$aInstitute of Medicine (U.S.).$bImmunization Safety Review Committee. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910970999303321 996 $aImmunization safety review$94356225 997 $aUNINA